Trastuzumab combined with lapatinib has previously demonstrated clinical efficacy in a patient with heavily pretreated inflammatory breast cancer containing HER2 V777L and S310F mutations.39 This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.